SPR Endorses an ACR Statement

The Board of Directors of the Society for Pediatric Radiology endorses the ACR Statement on Use of Iodinated Contrast Material for Medical Imaging in Young Children and Need for Thyroid Monitoring¹, a response to the FDA’s recommendation for thyroid monitoring in newborns and children through three years of age who receive injections of iodine-containing contrast media for medical imaging².  The Society for Pediatric Radiology supports the evidence-based safe imaging of children and advocates for further high-quality research on this topic.

References:

1. https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Use-of-Iodinated-Contrast-Material-for-Medical-Imaging-in-Young-Children
2. https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-thyroid-monitoring-babies-and-young-children-who-receive-injections-iodine-containing

APRIL 26, 2023 UPDATE: The U.S. FDA has updated its guidance to agree with the published literature, whereas universal thyroid testing is no longer recommended. The decision to test thyroid function after intravascular iodinated contrast material exposure should be based on a child's specific risk factors.  Read more here: https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-thyroid-monitoring-babies-and-young-children-who-receive-injections-iodine-containing